Supplementary




Figure S1 The study design diagram. NSCLC, non-small cell lung cancer; *EGFR*, epidermal growth factor receptor; QD, once daily; QOD, every other day; ORR, objective response rate; DCR, disease control rate; OS, overall survival; PFS, progression-free survival.

Table S1 Subject characteristics

| Characteristics | Number (n=11) | Percentage (%) |
|------------------|---------------|----------------|
| Age (years) | | |
| Median | 68 | |
| Range | 47–73 | |
| Gender | | |
| Male | 4 | 36.4 |
| Female | 7 | 63.6 |
| Smoking status | | |
| Never | 9 | 81.8 |
| Prior/current | 2 | 18.2 |
| Histology | | |
| Squamous | 0 | 0.0 |
| Non-squamous | 11 | 100.0 |
| EGFR mutation | | |
| Exon 19 deletion | 5 | 45.5 |
| Exon 21 L858R | 6 | 54.5 |
| CNS metastases | | |
| Yes | 9 | 81.8 |
| No | 2 | 18.2 |
| ECOG | | |
| 0–1 | 4 | 36.4 |
| ≥2 | 7 | 63.6 |
| EGFR-TKI choice | | |
| Osimertinib | 9 | 81.8 |
| Aumolertinib | 2 | 18.2 |

EGFR, epidermal growth factor receptor; CNS, central nerve system; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor.

Table S2 trAEs

| Table 32 trans | | | | |
|----------------------------|--------------------------|--------------------------------|--|--|
| AE term | Any trAE (n=9), n (%) | trAE grade 3–5 (n=9), n (%) | | |
| Skin disorders | | | | |
| Rash | 2 (22.2) | 1 (11.1)* | | |
| Respiratory disorders | | | | |
| Interstitial pneumonia | 1 (11.1) | 1 (11.1)* | | |
| Gastrointestinal disorders | | | | |
| Diarrhea | 1 (11.1)* | 0 (0.0) | | |
| Stomachache | 1 (11.1)* | 1 (11.1)* | | |
| Vascular disorders | | | | |
| Pulmonary embolism | 1 (11.1) | 1 (11.1)* | | |
| Metabolism disorders | | | | |
| Hyponatremia | 1 (11.1) | 1 (11.1)* | | |

Of note, there were no grade 5 trAEs observed on trial. *, led to the subject's discontinuation of the trial. trAE, treatment-related adverse event; AE, adverse event.